StockData
Virax Biolabs Group Ltd logo

Virax Biolabs Group Ltd (VRAX) stock

VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026Score 9/30
$0.43−0.02 (-3.39%)

Close on Nov 18, 2026Market cap $249.06KP/E –Yield –

Virax Biolabs shares outstanding

Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.

For fiscal 2026 it was 0M, up 166.5% from the year before. The highest annual figure on record is 0M in fiscal 2026.

Annual shares outstanding

PeriodPeriod endValueChange
FY2026Mar 31, 20260M+166.5%
FY2025Mar 31, 20250M+85.9%
FY2024Mar 31, 20240M+88.8%
FY2023Mar 31, 20230M+11.2%
FY2022Mar 31, 20220M+61.3%
FY2021Mar 31, 20210M–

More Virax Biolabs figures

See a number that looks wrong?